Boston Scientific Corporation (BSX) Financial Statements
Boston Scientific Corporation (BSX) reported trailing twelve-month revenue of $21.0B (up 13.5% year on year) and net income of $3.7B as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: $3.6B.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
BSXBoston Scientific CorporationFollow BSX — free
—
Price chart with a free account
- Market cap
- 66.2B
- P/E TTM
- 18.5
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 28 Oct, in 4 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2009 Dec 09 | FY2010 Dec 10 | FY2011 Dec 11 | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8.19 | 7.81 | 7.62 | 7.25 | 7.14 | 7.38 | 7.48 | 8.39 | 9.05 | 9.82 | 10.74 | 9.91 | 11.89 | 12.68 | 14.24 | 16.75 | 20.07 | 21.00 | |
| Gross profit | 5.61 | 5.21 | 4.96 | 4.90 | 4.97 | 5.17 | 5.30 | 5.96 | 6.46 | 7.01 | 7.62 | 6.45 | 8.18 | 8.73 | 9.90 | 11.49 | 13.85 | 14.68 | |
| Research & development | 1.04 | 0.94 | 0.90 | 0.89 | 0.86 | 0.82 | 0.88 | 0.92 | 1.00 | 1.11 | 1.17 | 1.14 | 1.20 | 1.32 | 1.41 | 1.62 | 2.05 | 2.15 | |
| Operating income | -0.89 | -0.66 | 0.90 | -3.87 | 0.12 | -0.30 | -0.28 | 0.45 | 1.29 | 1.51 | 1.52 | -0.08 | 1.20 | 1.65 | 2.34 | 2.60 | 3.61 | 4.15 | |
| Pre-tax income | -1.31 | -1.06 | 0.64 | -4.11 | -0.22 | -0.51 | -0.65 | 0.18 | 0.93 | 1.42 | 0.69 | -0.08 | 1.08 | 1.14 | 1.99 | 2.28 | 3.39 | 3.86 | |
| Income tax | -0.28 | 0.00 | 0.20 | -0.04 | -0.10 | -0.39 | -0.41 | -0.17 | 0.83 | -0.25 | -4.01 | 0.00 | 0.04 | 0.44 | 0.39 | 0.44 | 0.49 | 0.19 | |
| Net income | -1.03 | -1.07 | 0.44 | -4.07 | -0.12 | -0.12 | -0.24 | 0.35 | 0.10 | 1.67 | 4.70 | -0.08 | 1.04 | 0.70 | 1.59 | 1.85 | 2.89 | 3.67 | |
| Diluted EPS ($) | -0.68 | -0.70 | 0.29 | -2.89 | -0.09 | -0.09 | -0.18 | 0.25 | 0.08 | 1.19 | 3.33 | -0.08 | 0.69 | 0.45 | 1.07 | 1.25 | 1.94 | 2.47 | |
| Diluted shares (bn) | 1.508 | 1.518 | 1.519 | 1.407 | 1.341 | 1.324 | 1.341 | 1.377 | 1.393 | 1.401 | 1.411 | 1.417 | 1.434 | 1.440 | 1.464 | 1.486 | 1.494 | — |
USD billions · SEC XBRL
Boston Scientific Corporation — questions
- What is Boston Scientific Corporation's revenue?
- $21.0B over the twelve months to 2026-06-30, up 13.5% year on year, from its 10-Q and 10-K filings.
- What is Boston Scientific Corporation's net income?
- $3.7B over the twelve months to 2026-06-30.
- What is Boston Scientific Corporation's free cash flow?
- $3.6B over the twelve months to 2026-06-30.
- What are Boston Scientific Corporation's diluted earnings per share?
- $2.47 over the twelve months to 2026-06-30.
Every figure on this page comes from Boston Scientific Corporation's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.